N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The objective of this application is to examine whether, given its mechanism of action, the
dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and pathological
gamblers (PG) symptoms in nicotine dependent pathological gamblers.
Phase:
Phase 2
Details
Lead Sponsor:
University of Chicago Yale University
Collaborators:
National Institute on Drug Abuse (NIDA) University of Minnesota University of Minnesota - Clinical and Translational Science Institute